John Jenkins’ retirement decision faced a few starts and stops before being finalized.
The long-time Office of New Drugs director, who has spent nearly 25 years at FDA and 32 years in public...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?